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Abstract
Different bacteria-derived systems for regulatable gene expression have been developed for the use in mammalian cells and
some were also successfully adopted for in vivo use in vertebrate model organisms. However, certain limitations apply to
most of these systems, including leakiness of transgene expression, inefficient transgene silencing or activation, as well as
limited tissue accessibility of transgene-inducers or their unfavourable pharmacokinetics. In this study, we evaluated the
suitability of the lac-operon/lac-repressor (lacO/lacI) system for the regulation of the well-established Vav-gene promoter
that allows inducible transgene expression in different haematopoietic lineages in mice. Using the fluorescence marker
protein Venus as a reporter, we observed that the lacO/lacI system could be amended to modulate transgene-expression in
haematopoietic cells. However, reporter expression was not uniform and the lacO elements introduced into the Vav-gene
promoter only conferred limited repression and reversion of lacI-mediated gene silencing after administration of IPTG.
Although further optimization of the system is required, the lacO-modified version of the Vav-gene promoter may be
adopted as a tool where low basal gene-expression and limited transient induction of protein expression are desired, e.g. for
the activation of oncogenes or transgenes that act in a dominant-negative manner.
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Introduction
Transgenesis in mice has become a useful tool to study gene
function and model human diseases in vivo. Examples of
transgenic mouse strains generated to study oncogenesis in the
haematopoietic system include, amongst others, mice overex-
pressing anti-apoptotic Bcl-2 to model follicular B cell lympho-
mas, a mutated version of N-Ras driving T cell and histocytic
lymphomagenesis, the BCR-abl fusion protein driving chronic
myelocytic leukemia and cases of acute myelocytic leukemia in
humans or the c-Myc proto-oncogene under the control of the Ig-
heavy chain enhancer (Em) that develop aggressive preB and
IgM
+ B cell lymphomas, mimicking to a certain degree features of
Burkitt lymphoma [1].
Although transgenicmice aresuitable modelsto study a varietyof
pathological states, certain restrictions apply. One of the problems
connected with transgene overexpression is putative cytotoxicity,
sometimes associated with induced lethality, but more frequently
silencing of transgene expression and counter-selection of cells with
low or no transgene expression. Another limitation is related to the
fact that expression of the target gene may be only desired in a
specific cell type, at a specific developmental stage or for a limited
time frame to better mimic events during normal development or
human disease pathology. To overcome these problems, tissue
specific transgenesis has been developed that aims to exploit certain
regulated gene-expression systems derived from bacteria, e.g. the
tetracycline-based TetON/OFF system developed by Bujard and
colleagues [2], or, for nuclear acting transgenes such as Cre
recombinase, estrogen-receptor (ER)-fusion proteins that can be
retained in the cytoplasm and translocate into the nucleus upon
application of the synthetic ligand, 4-hydroxytamoxifen (4-OHT)
[3]. Although well established in cell lines and today frequently used
in transgenic mouse strains, certain limitations apply to these
systems, mainly insufficient tightness of gene-repression and/or
moderate induction levels, e.g., due to ineffective delivery and
targeting of agonists to the cell type/tissue of interest, as well as
stochastic epigenetic transgene silencing [4–5].
Therefore, we aimed to combine a tissue-specific transgene
expression system with an inducible one that would allow
regulated transgenesis in the haematopoietic system. We chose
the promoter of the Vav gene, expressed in the entire hematopoi-
etic lineage but few other cell types, showing good expression levels
in all cell types of the blood, including multipotent progenitors as
well as haematopoietic stem cells [6]. This promoter has been
already used successfully for the expression of Bcl-2 [7], Mcl-1 [8]
or Cre-recombinase [9] in the hematopoietic compartment and is
most suitable when consequences of transgene expression need to
be studied in the context of more than just a single haematopoietic
cell type. To generate a system that may also provide tight and
reversible control of the Vav-gene promoter we chose to explore
the suitability of the lac repressor/operator (lacI/lacO) system
previously be shown to allow timed and reversible transgene
expression in mice [10,11]. Insertion of three lacO sites into the
VavP transgenic vector did allow expression of a fluorescent
reporter protein, Venus, in a manner comparable to unmodified
VavP promoter. Notably, reporter expression appeared variegat-
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reduced in double-transgenic mice in which the lac repressor was
expressed ubiquitously under the control of the human b-actin
promoter [10]. However, the efficiency of re-expression of the
reporter in different cell types was highly variable and cell type
dependent, indicating and the need for further optimization for
satisfying use in haematopoietic cells in vivo.
Results
1) Insertion of lacO elements into the VavP vector confers
IPTG sensitivity
We chose to adopt the Vav-gene promoter, demonstrated to
confer tissue specific expression of transgenes in vivo [6], in
order to make it amenable to timed regulation. A DNA element
derived from the pOPI3CAT expression vector containing three
symmetric lac operator (lacO) binding sites recognized by the lac
repressor (lacI), within a SV40-derived intron, was subcloned
between the transcription start site of the endogenous Vav-gene
and the multiple cloning site (MCS) of the HS21/45 VavP-
transgenic vector. Venus, an optimized version of GFP [12], was
inserted as a reporter into the MCS (Fig. 1a). The insertion was
confirmed by sequencing and the VavlacOVenus (VLV) construct
was tested for functionality by transient transfection into 293T
cells, either alone or together with a plasmid encoding the codon
optimized mammalian version of the lacI [10]. Inspection of cells
in an immunofluorescence microscope followed by flow
cytometric analysis confirmed expression of Venus in a subset
of cells transfected with the VLV plasmid alone that was
reduced when co-expressed along with a lacI-encoding plasmid
(Figs. 1b,c). Quantification by flow cytometry revealed that co-
expression of lacI indeed reduced the percentage of Venus
+ cells
from ,24% to ,10%, while addition of the synthetic inducer
IPTG lead to a significant (p,0.05) increase in Venus
expression (Fig. 1c). Increasing the concentration of IPTG
further to 0.1 or 1 mM did not significantly improve the efficacy
of re-induction, consistent with published results using embry-
onic R3 cells [10]. Venus encoding cDNA was also subcloned
into an unmodified version of the Vav-transgenic vector (VV)
that served as a control. The percentage of Venus expressing
293T cells was comparable between VLV and VV transfected
cells (Fig. 1c) demonstrating that the insertion of the SV40-
intron did not compromise the activity of the Vav promoter, at
least in vitro.
Figure 1. Generation of an IPTG-responsive version of the Vav-transgenic vector. (a) Schematic representation of the modified VavP HS21/
45 plasmid (VLV) where three lac repressor binding sites (lacO, sequence in red) were introduced in the SV40 intronic sequence upstream of the
multiple cloning site, bearing the Venus cDNA. (b) Functionality of the construct was assessed before oocyte-injection by transient transfection into
293 T cells in the presence or absence of a construct encoding for the lacI repressor followed by flow cytometric analysis. (c) 293 T cells transfected
with empty vector, VV, VLV 6 lacI were exposed to different doses of isopropyl b-D-1-thiogalactopyranoside (IPTG) and 24 h later the percentage of
Venus
+ cells was quantified by flow cytometric analysis. Bars represent means 6 SEM of a representative experiment performed in triplicate *p,0,01,
#p,0.05.
doi:10.1371/journal.pone.0018051.g001
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Transgenic mice were generated by microinjection of the VLV
or VV constructs isolated as a linear fragment into fertilized
oocytes from FVB mice. PCR genotyping on tail DNA using
primers specific for Venus cDNA and VavP cassette sequence was
performed to identify founders carrying the transgene (Fig. 2a).
Since transgene insertion does not necessarily result in its
expression, e.g. due to silencing or positioning effects in
heterochromatin, we collected peripheral blood (PB) from PCR
+
and PCR
2 mice and performed flow cytometric analysis to verify
the typing results and quantify the percentage of Venus-expressing
cells. Venus expression in the peripheral blood varied significantly
between founders, indicating that some of the founders were
mosaic or may show variegated transgene expression e.g., due to
positioning effects of the transgene (Fig. 2b,c). Out of the
transgene-expressing founders, we chose those showing highest
Venus expression for further breeding, i.e. VLV A1 and A3 as well
as VV A9 and A19. All experiments shown below are derived
using VLV A3 and VV A9 derived progeny, respectively. Similar
results regarding heterogeneous transgene expression were also
observed in the offspring of other founders (not shown).
3) Expression of Venus protein is detectable in myeloid
and lymphoid cells but appears variegated
Although the transgenic animals did not show any overt
phenotype up to an observation period of 6 month, we wanted to
monitor whether overexpression of Venus could have some impact
on lymphocyte number or survival, since high level expression of
GFP has been reported to cause some toxicity in cultured cells [13]
and reportedly correlated with premature lethality when overex-
pressed strongly in cardiomyocytes [14]. First, we performed
Western blot analysis on different tissues that confirmed restriction
of transgene expression to haematopoietic organs (Fig. 3a). Next,
we quantified leukocyte numbers in haematopoietic organs and
compared transgenic lines with littermate controls that failed to
reveal any significant differences (p.0.2) in cell number (Fig. 3b).
Second, we put primary lymphocytes derived from thymus, spleen
or lymph nodes in culture and monitored cell survival by Annexin
V/PI staining, in combination with cell surface marker staining to
identify T and B cells, over time. Thymocytes as well as mature B-
and T-cells derived from the spleen of the VLV or VV mice did
not show any difference in survival in culture when compared to
those ones derived from wt mice (Fig. 3b). Unexpectedly, the B-
cells derived from the lymph nodes of VLV mice appeared more
resistant to spontaneous apoptosis than the ones of VV or wt mice
that died with similar kinetics (Fig. 3b). Together our results show
that Venus expression is well tolerated in lymphocytes over time in
vivo. Also, in the VLV strain chosen for detailed analysis, transgene
insertion may influence expression/function of gene(s) associated
with the survival of mature B cell, at least in vitro. However, since
we did not observe B cell accumulation in vivo this observation was
not followed up in detail.
We continued our analysis quantifying the percentage of
Venus
+ cells in different primary and secondary lymphatic organs.
Therefore, we stained single cell suspensions with antibodies
specific for different cell surface markers, identifying T-cells, B-
cells or myelocytes and performed flow cytometric analysis.
Venus
+ cells were found in all the leukocyte subpopulations tested.
However, the relative percentage of Venus
+ cells varied between
the individual transgenic lines as well as between littermates,
indicating variegated expression of the reporter or mosaicism due
to stochastic gene silencing. Similar observations were made in all
other lymphoid organs analyzed (Fig. 4a). In VLV transgenic
mice, T cells showed Venus expression in all the organs ranging
from 35%–80%, with highest expression found in CD8
+ T cells in
lymph nodes and spleen (,80%), while the percentage of Venus
+
CD4
+ T cells was frequently lower in thymus, peripheral blood,
spleen, lymph node and bone marrow (p,0.03) (Fig. 4b). In the
CD19
+ B cell compartment in the periphery, we found that
transgene expression was actually highly comparable between
spleen, peripheral blood and bone marrow with 70–80% of Venus
expressing B cells, but only about half of the B cells in the lymph
node were expressing the transgene (Fig. 4b). Immature pro- and
pre-B-cells in the bone marrow also expressed Venus, with a
slightly higher percentage of transgene positive pro-B than pre-B
cells (Fig. 4b). The percentage of Venus
+ Mac1
+ myelocytes was
comparable to the percentage of Venus
+ lymphocytes in the
spleen, while it was significantly lower in the bone marrow and
peripheral blood (p,0.002) of VLV mice (Fig. 4b). Comparing
levels of Venus
+ cells in the VLV with those in VV transgenic mice
we noticed an overall similar pattern of transgene expression but a
generally lower percentage of Venus
+ cells in the VV strain (Fig.
4b). This phenomenon is most likely due to different sites of
insertion of the transgene and/or copy number variation. Notably,
qPCR analysis performed on tail DNA derived from three
randomly picked animals of each strain revealed an about 2.5-
fold higher signal for Venus in the VV samples, indicating higher
copy number in this strain (not shown). This suggests that
chromatin effects at the site of integration rather than copy
number accounts for the difference in transgene expression
between the two strains.
4) Gene-silencing of Venus expression in VavLacOVenus/
LacI double transgenic mice
After having characterized Venus expression in the single
transgenic mice, we started to cross VLV mice with mice
transgenic for lacI. In these animals the Lac repressor protein is
ubiquitously expressed from the human b-actin promoter, with
high levels of repressor protein detected in the spleen [10]. First we
started to analyze if Venus expression was shut down effectively in
the peripheral blood of double-transgenic mice identified by PCR
genotyping, using flow cytometric analysis and whether it was re-
inducible in culture. Venus expression in the peripheral blood
dropped to ,5% in double-transgenic animals, indicating effective
shut down of transgene expression. We were also able to re-induce
Venus expression upon IPTG treatment in a significant portion of
the cells (p,0.05), monitored up to 72 h and reaching plateau
after 48 h with up to 30% of the cells re-expressing Venus (Fig.
5a). The dose-response behaviour of the cells suggested that the
system was already maximally induced with 10 mM of IPTG, but
Venus expression levels appeared more stable at later time-points
when $50 mM IPTG were used, the concentration we chose for
further experiments. When monitoring the percentage of mitogen-
induced Venus
+ T or B cells blasts derived from peripheral blood
over time by gating on TCRb
+ T or CD19
+ B cells, respectively,
no significant difference was observed between the cell types
(p=0.23), but we were unable to reach the percentage of Venus
+
cells observed in the peripheral blood from single transgenic VLV
mice (Figs. 5b–d). Extended culture of cells was not increasing the
percentage of Venus
+ cells, probably due to the high rate of cell
death occurring in the T and B cell blasts over extended times ex
vivo which ultimately associated with loss of Venus expression (not
shown).
Next, we aimed to verify whether the system was inducible in
vivo. First, we started to treat the animals with 10 mM IPTG in the
drinking water, as suggested by previous results using a regulated
version of the tyrosinase gene [10]. However, after monitoring
Venus expression after 1 and 3 weeks of IPTG-treatment,
Vav-Driven lacO/lacI System in the Mouse
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18051Figure 2. Identification of transgenic mice. The VavLacOVenus (VLV) plasmid as well as an unmodified version of the VavP plasmid encoding
Venus cDNA (VV) were digested with AseI and PvuI and an approximately 9.2 kb AseI-PvuI fragment was used for microinjection into fertilized FVB
oocytes. (a) Transgenic founders were first identified by PCR genotyping on tail DNA. VLV = VavLacOVenus transgenic mouse, VV = VavVenus
transgenic mouse, WT = wild type FVB mouse. (b) Histograms from flow cytometric analysis showing different levels of transgene expression in PCR-
typed founders. (c) Range of transgene expression levels in PCR
+ founders, quantified as in (b).
doi:10.1371/journal.pone.0018051.g002
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18051Figure 3. Characterization of Venus expression, organ cellularity and lymphocyte survival in vitro. (a) Protein lysates (55 mg/lane) from the
indicated organs harvested from wt or VLV mice were separated by SDS-PAGE, transferred onto nitrocellulose membranes and immunoblotting was
performed using an antiserum generated against GFP. Membranes were reprobed using a monoclonal antibody recognizing GAPDH to demonstrate
comparable protein loading. *MLN = mesenteric lymph nodes. (b) Mice of the indicated genotpyes 6-8 weeks of age were sacrificed to evaluate organ
cellularity (n=4/genotype). Primary cells derived from total spleen, thymus or lymph nodes were put in culture and spontaneous apoptosis was
quantified by flow-cytometry. Markers for T- (CD3) and B-cells (CD19) were used in combination with AnnexinV-APC+7-AAD staining to monitor survival
over time. Data points represent means 6 SEM of three independent experiments (1 =p .0.001 VLV vs VV and WT, # =p .0.01 VLV vs VV and WT).
doi:10.1371/journal.pone.0018051.g003
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e18051respectively, we were unable to detect a significant portion of
treatment-induced Venus
+ cells in the peripheral blood of these
animals. In line with our organ analysis, CD8
+ T cells that showed
highest levels of transgene expression (Fig. 4), showed best
induction in a subset of cells (up to 10%), while induction in
other T and B cell subset was detected in less than 5% of the cells
(data not shown). So we decided to treat the mice with a single
dose of IPTG i.p. In a pilot experiment, we treated 8 weeks old
animals with graded doses of IPTG (0.1, 1 or 10 mg) and
monitored the percentage of Venus
+ cells in peripheral blood over
time. As in our in vitro experiments, no substantial differences were
noticed between the three doses tested and 1 mg IPTG was chosen
for further experiments (data not shown). We collected peripheral
blood from the tail vein of treated animals in different intervals
and stained cells with antibodies specific for different cell surface
markers identifying myelocytes, T and B cells. Similar to our in
vitro experiments we were able to detect a significant increase
(p,0.05) in percentage of Venus
+ cells in the peripheral blood of
double-transgenic mice, with CD8
+ T cells and IgM
+D
2 naı ¨ve B
cells showing the best response while Mac-1
+ myelocytes only
responded poorly, if at all (Fig. 6). However, variation in gene
silencing was high with CD8
+ T cells showing the highest leakiness
in double transgenic mice. In none of the cell types analyzed were
we able to induce Venus expressing to the levels noted in single
transgenic mice (Fig. 6).
Discussion
We adopted the expression plasmid VavP21/45, containing the
promoter of the Vav gene, to drive expression of a fluorescent
Figure 5. Transgene silencing and re-expression of transgene expression in vitro. Primary cells derived from peripheral blood of VLV/LacI
double transgenic mice were put in culture and stimulated with graded doses of IPTG. FACS analysis was performed at the indicated time points to
monitor levels of Venus
+ cells (a). Peripheral blood lymphocytes from mice of the indicated genotypes were stimulated with IL-2+PMA+ionomycin to
drive T-cell activation or IL-2+IL-4+IL-5+LPS to drive B-cell proliferation. Proliferating cells were treated with 50 mM IPTG on day 3 after mitogen
stimulation and levels of Venus
+ cells were quantified by FACS analysis on all cells (b), as well as T-cells (c) or B-cells (d). Results from four
independent experiments and 4-9 animals/genotype (wt=5, LacI n=5, VLV n=4, VLV/LacI n=9) are represented as box plots. Box length equals
interquartile range. Circles represent minimal and maximal values; *p,0.001; #p,0.05. F2 generation offspring of VLV founder A3 were crossed with
LacI mice. Single-, double-, and non-transgenic littermates were used for analysis.
doi:10.1371/journal.pone.0018051.g005
Figure 4. Characterization of transgene expression in haematopoietic cells from VLV and VV mice. Animals that proved positive for
Venus expression in the peripheral blood were sacrificed for further analysis of transgene expression in different organs. (a) Single cell suspension
from spleens were stained with fluorochrome labeled antibodies specific for cell surface markers identifying T cells (CD4, CD8), B cells (CD19), as well
as myelocytes (Mac-1) and subjected to flow cytometric analysis. Representative dot blots showing variegate expression of the transgene are shown.
(b) Summary of the experiments shown in (a), performed to assess the percentage of transgene expressing leukocytes in all major haematopoietic
organs. Bars represent means 6 SEM (wt n=8, VLV n=5, VV=3); *p,0.001; #p,0.05. P values refer to significant differences in Venus expression
between cells derived from VLV and VV mice. F2 generation offspring of VLV founder A3 and F3 generation offspring of VV founder A9 were used for
this analysis, as well as transgene-negative littermate controls of both strains.
doi:10.1371/journal.pone.0018051.g004
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We confirmed functionality and regulation of reporter expression
after insertion of lacO binding sites by LacI after IPTG treatment in
293T human embryonic kidney cells (Fig. 1). In the presence of a co-
transfected Lac repressor, the percentage of Venus
+ cells was
reduced but not completely shut down, consistent with previous
results ectopically expressing a lacO-modified version of the human
huntingtin promoter driving firefly luciferase [10,15]. Initially, we
ascribed the limited expression and silencing to the fact that a
heterologous cell system was used where the Vav-gene is usually not
active [6]. Also, the addition of IPTG to the cell culture media only
partially restored original levels of Venus expression in 293T cells,
which has been noted before when using this system in mammalian
cells [16]. Incomplete shut-down of transgene expression might be
related or due to the spacing and positioning of the lacO elements in
close proximity and short distance within the pOPI3-CAT-derived
SV40 intron, upstream of the multiple cloning site. It has been
reported before, that two lacO sites positioned on either site of the
transcription start site are sufficient to confer regulation to
mammalian promoters by lacI and IPTG, while the third binding
side is usually positioned further up or downstream and mainly
servestoincreasethelocalconcentrationoflacI[11].However,since
we did not want to interfere with the tissue-specificity of the VavP
promoter-construct, we were prepared to accept reduced promoter
regulation in our initial in vivo approach using Venus as a reporter.
When assessing transgene expression in peripheral blood of the
founders, we found a high variation in the percentage of Venus
+
cells (Fig. 2), a possible consequence of the microinjection
technique used to generate transgenic animals, where copy
number and insertion sites can vary and mosaicism is frequently
observed due to transgene insertion at the two cell stage or later.
However, consistent with the heritable nature of position effect
variegation (PEV) [17], transgene expression was also observed to
vary in F2 progeny of selected founders. Based on our organ
analysis, this appeared to vary strongly between cell types and
tissues (Fig. 4). Our results resemble those reported initially when
using the bacterial b-gal gene as a reporter in the context of the
VavP promoter that was expressed in a variegated manner and
subjected to frequent silencing over time [18]. PEV is a well
known phenomenon in transgenesis depending on chromatin
structures near the site of insertion, most pronounced when
transgene constructs are used that lack a defined locus control
region [17], but also hard to distinguish in our case from gene
silencing-induced mosaicism. Based on experiences using hCD4 or
hBcl-2 as transgenes in the VavP vector showing uniform
expression of the human transgenes tested [6,7], we can only
speculate that the non-mammalian Venus sequence, although
codon optimized for the use in mammalian cells, may be
susceptible to stochastic epigenetic silencing in a certain percent-
age of cells, as was observed previously when VavP-lacZ tg mice
were compared to VavP-hCD4 tg mice [6,7]. Alternatively, the
pOPI3-CAT derived SV40-derived intronic sequence containing
the lacO sites may be subjected to epigenetic silencing, as noted
before when bacterial or viral sequences were introduced into
Figure 6. Transgene re-expression in vivo. Mice of the indicated genotypes were treated i.p. with 1 mg IPTG and levels of Venus
+ cells in T-, B-
and myeloid subsets in the peripheral blood were quantified by FACS analysis following the indicated times. Results of three independent
experiments and 3 (VLV and LacI) or 6 (VLV/LacI) animals/genotype are represented as box plots. Box length equals interquartile range. Circles
represent minimal and maximal values; *p,0.001; #p,0.05. F2 generation offspring of VLV founder A3 were crossed with LacI mice. Single-, double-,
and non-transgenic littermates were used for analysis.
doi:10.1371/journal.pone.0018051.g006
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since we noted similar patterns of transgene expression in the VV
strain, lacking this DNA element (Fig. 5). Since we were forced to
use different restriction enzymes to linearize the modified VLV
plasmid, it remains also possible that the residual bacterial DNA
sequence of about 250 base pairs that we could no longer remove
(Fig. 1a) may render the transgene more susceptible to silencing.
Alternatively, high-copy number insertion of transgenes reportedly
favours variegation of expression due to repeat-induced gene
silencing [17] which may in part explain why VV mice, that do
have a higher copy number insertion than VLV mice based on
qPCR analysis (not shown), showed stronger variegation (Fig. 4).
Alternatively, high-level expression of Venus may not be well
tolerated in haematopoietic cells causing silencing of transgene
expression over time or counter selection in stem cells. High-level
GFP expression was reported to induce apoptosis in cultured cells
and cardiomyopathy was observed in FVB mice with high-level
expression of GFP when driven from the cardiac alpha-myosin
heavy chain promoter [14]. However, our in vitro analysis did not
show increased cell death in Venus expressing lymphocytes (Fig. 2)
and counter selection due to toxicity in leukocytes can be largely
excluded since we did not see a significant reduction of the
percentage of Venus
+ cells in peripheral blood over time (not
shown).
When we crossed our single transgenic VLV mice with the LacI
repressor mice we noticed that reporter transgene expression was
actually quite effectively silenced in the peripheral blood where
only about 5% of cells scored as Venus
+ by highly sensitive flow
cytometry. In addition, emission of Venus fluorescence is
significantly stronger as the one emitted by GFP [12], which
initially suggested that silencing is very effective and well in the
range or even better as when the Bujard system was used in vivo
[20]. This background expression of Venus did not differ
significantly between cell types of the peripheral blood (Fig. 4)
making broad differences in lacI expression across the different
haematopoietic cell types analyzed unlikely. However, when
testing for the ability to re-induce transgene expression in vitro,
we noted that we were unable to reach more than 30% Venus
+ T
or B cell blasts (Fig. 5). While this may have been due to high rates
of cell death that correlates with loss of Venus expression in
primary lymphocytes upon extended in vitro culture, application of
IPTG in the drinking water also failed to drive transgene re-
expression in peripheral blood (not shown). This may be due to the
reported short half-life and rapid clearance of IPTG from the
peripheral blood stream by excretion via filtration in the kidneys
[21] but should not be an issue in vitro. Similarly, when injecting
mice with IPTG i.p., we also noted a very limited response,
combined with considerable leakiness in different cell types that
again differed between individual animals (Fig. 6). Notably, either
repression was good, i.e. less than 10% of the cells were Venus
+
then re-induction was also poor (20–30%), or the system was leaky
(.20% Venus
+ cells) allowing high levels of re-induction (up to
80%, e.g. in CD8
+ T-cells). This opens the possibility that the
inefficient shut down and leakiness observed may be related or due
to inefficient expression of lacI by the b-actin promoter in different
haematopoietic cell types. In previous studies characterizing LacI
tg mice the levels of LacI protein expression was only assessed in
tissue lysates but not at the cellular level [10,15], leaving the
possibility that its expression may actually be also not uniform
across cell types within tissues. Alternatively, the Vav-gene
promoter that shows differences in activity in between leukocyte
subsets and is highly susceptible to epigenetic regulation [18] may
either be too weak to overcome the repressive effect of LacI in all
cells of a given lymphocyte subset before clearance of the inducer,
or, become more easily subjected to heterochromatinization e.g.,
due to lacI-mediated inefficient transgene expression, favouring
such events in some type of negative feed back loop. However, this
needs to be formally demonstrated.
Our findings using the lacO/lacI system in haematopoietic cells
differ from the successful use of this system driving tyrosinase
expression in pigment-producing melanocytes, suggesting that
these cells are able to accumulate more inducer and maybe retain
higher level/constant expression of LacI. Furthermore, re-
expression of the transgene in a subset of hair follicle stem cells
or derived melanocytes may actually be sufficient to restore
pigmentation [10].
Although, the lacO/lacI system in the current version tested
shows only limited suitability for regulated transgenesis in
haematopoietic cells, after optimization, e.g., of lacO element
number/positioning and/or reduction of transgene copy number,
it may still be useful for certain applications. Variegated or mosaic
expression of Venus may even be exploited to target expression of
pro-apoptotic genes, recombinases or transforming oncogenes only
to a subset of cells, e.g., by inserting an IRES-element in the
39UTR of Venus, followed by the cDNA of interest. Alternatively,
the same trick can be exploited to introduce an RNA interference
based gene-silencing cassette, eliminating expression of a target
gene in a subset of cells.
Materials and Methods
Generation of transgenic mice & vector manipulation
Animal experiments were in accordance with Austrian law and
approved by the Austrian Ministry for Science and Education
(BMBWK-66011/0136-BrGT/2006). A 484 bp SV40-derived
intronic sequence fragment derived from the pOPI3CAT plasmid
(Stratagene), containing 3 symmetric lacO sites (http://www.
genomics.agilent.com/files/Vectors/Sequences/opi3cat_s.txt) was
excised by BglII digest and subcloned after fill-in and NotI digest
into partially NaeI, EagI digested VavP21/45 transgenic vector.
The transgenic lines VavLacOVenus and VavVenus were generated by
microinjection of a 9.2 kb AseI-PvuI fragment gel purified from
the corresponding plasmids. The DNA was microinjected at
approximately 2–3 ng/ml into the pronuclei of fertilized oocytes
from FVB mice (Charles River Laboratories) at the one-cell stage
following standard procedures. Founders containing .80% of
Venus
+ cells in the peripheral blood were chosen to establish
transgenic lines. Due to variegated transgene expression, the
percentage of Venus
+ cells was determined from peripheral blood
and only mice with .80% of Venus
+ cells in F2 were used for
further breeding with non-transgenic mice to maintain a
hemizygous state. Double-transgenic mice were generated by
intercrossing VLV mice with FVB b-actin LacI transgenic mice
[10].
DNA extraction and PCR typing
DNA was extracted from tail tips digested overnight at 55uCi n
500 mL of 50 mMTris (pH 8), 200 mM NaCl, 0.5% SDS, 5 mM
EDTA and 2 mg/ml Proteinase K. Undigested material was
sedimented by centrifugation and 350 mL was transferred into a
clean 1.5 ml tube. DNA was extracted by isopropanol precipita-
tion (1:1; v/v) followed by centrifugation in a microfuge (2 min,
13.000 rpm, 4uC). The pellet was washed once in 1 ml 70%
ethanol. After another centrifugation step, the pellet was air-dried
and resuspended in 100 mLT Ea t5 5 uC for about half an hour.
1 ml was used per PCR reaction.
Littermates from heterozygous VavLacOVenus or VavVenus mice
were genotyped on tail DNA by PCR using primer pairs specific
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respectively. The following cycle conditions were used: 5 min at
94uC;40 sat94uC,30 sat60uC,and3 minat72uC(35cycles);and
10 min at 72uC. VavLacOVenus allele primers: forward, 5_-CC-
TAGGTTGTGGAATTGTGAG-3, and reverse 5_- CCAGGG-
CACGGGCAGCTT-3, (330 bp product); VavVenus allele prim-
ers:forward,5_-GCCTGCAGTGCTTCGCCCGC-3,andreverse
5_-GCTTGTCGGCGGTGATATAGACG-3, (250 bp product).
Littermates from heterozygous VLV/LacI double transgenic
mice were genotyped by PCR using primer pairs specific for
SV40/Venus sequence (as described above) and lacI respectively.
The following cycle conditions were used for lacI PCR: 5 min at
95uC; 30 s at 95uC, 15 s at 63uC, and 1 min at 72uC (30 cycles);
and 10 min at 72uC. lacI allele primers: forward, 5_-GCACTC-
CAGTCACCTTCTCTTTCA-3, and reverse 5_-TGGGAGC-
CTCTG TGGTGGTGTCAA-3, (450 bp product).
IPTG treatment in vivo and peripheral blood sampling
IPTG (SIGMA-Aldrich) was dissolved in sterile water to a final
concentration of 5 mg/ml. Animals were injected i.p. with 1 mg
IPTG in 200 ml of a freshly prepared solution or IPTG was
provided in drinking water 10 mM/1%glucose in light-protected
bottles, changed in 2–3 day intervals. Mice were anesthetized by
Isofluorane inhalation (ABBOTT Laboratories) and then periph-
eral blood was collected from a lateral tail vein or the retrobulbar
vein plexus. Heparin (Ebewe Pharma) was added to the 1.5 ml
collection tube (10 ml) to avoid blood coagulation.
Generation of T- or B-cells blasts and IPTG treatment in
vitro
Samples from peripheral blood were subjected to red blood cell
lysis for 5 minutes at 37uC followed by repeated washing in 1 ml
PBS and centrifugation (4uC, 5 minutes, 1500 rpm). Cell pellets
were resuspended in RPMI 1640 medium, supplemented with
250 mM L-glutamine, 50 mM 2-mercaptoethanol, penicillin/
streptomycin (1 U/ml), 10% FCS, non-essential amino acids
(Invitrogen) and 1 mM pyruvate (Invitrogen). For the generation
of T-cell blasts, medium was complimented with 100 U/ml of
mIL-2 (Peprotech) and 2 mg/ml Concanavalin A (Sigma-Aldrich).
For the generation of B-cell blasts, medium was complemented
with 100 U/ml of mIL-2, 10 mg/ml mIL-4, 10 mg/ml mIL-5 (all
Peprotech) and 20 mg/ml LPS (Sigma-Aldrich). Cells were
cultured for 3 days and allowed to form blasts prior stimulation
with 50 mM IPTG. Aliquots of the cultured cells were recovered,
centrifuged (5 min, 1500 rpm, RT) and washed once in excess
PBS prior antibody staining and flow cytometric analysis. Cell
pellets were resuspended in 200 ml of PBS containing 2% rat
serum plus either anti-TCRb-PE or anti-CD19-PE (Biolegend),
diluted 1:200 and incubated for at least 30 min on ice in the dark.
Flow cytometric analysis was performed to monitor induction of
Venus expression in T or B cell blasts over time.
Cell culture and transient transfection
Cells were cultured at 37uC in a humidified atmosphere
containing 5% CO2. 293 T human embryonic kidney cells
(ATCC, CRL-11269) were cultured in the DME medium
supplemented with 10% FCS (PAA), 250 mM L-glutamine
(Invitrogen) and penicillin/streptomycin (1 U/ml, Sigma-Aldrich).
Primary thymocytes, lymph node and spleen cells were cultured in
RPMI 1640 medium, supplemented with 10% FCS (PAA),
250 mM L-glutamine (Invitrogen), 50 mM 2-mercaptoethanol,
penicillin/streptomycin (1 U/ml, Sigma-Aldrich), non-essential
amino acids (Invitrogen) and 1 mM pyruvate (Invitrogen).
293T human embryonic kidney cells were transiently transfect-
ed in 6-well plates using 3ı `l of Lipofectamine 2000 reagent
(Invitrogen) and a total of 1ı `g of plasmid DNA. Cells were seeded
at a density of 1610
5/well the night before. During transfection
cell were incubated in 1 ml Optimem (Gibco) and 250 mlo f
Lipofectamin (Invitrogen) mix was added for 6–16 h before
replacing Optimem with regular culture medium after a single
wash with PBS. After culture for 24 h, IPTG (tested in a range
between 0.1 mM–1 mM) was added for additional 24 h. After
48 h cells were collected by trypsinization, along with their
supernatant and centrifuged for 5 minutes, at 4uC, 1500 rpm.
Pellets were then resuspended in PBS and flow cytometric analysis
was performed to determine percentage of Venus positive cells
using a FACS_Calibur instrument (Becton Dickinson).
Immunoblotting
Mouse tissues were flushed in PBS, snap frozen on dry ice and
subsequently lysed in RIPA buffer containing protease inhibitors
(Roche) in a tissue grinder (MP Biochmedicals) set at 6 m/sec for
40 seconds using FAST-Prep lysis matrix D containing silica
spheres (MP Biochmedicals) in a 2:1 v/w ratio. Suspensions were
kept on ice for 60 min, insoluble material was spun down in a
microfuge (3 min, 13.000 rpm, 4uC) and the supernatant
transferred into fresh tubes. Aliquots of lysates were used for
protein quantification by Bradford (Biorad), stored at 280uC.
50 mg of total protein extracts were separated denatured and
boiled in 56 Laemmli sample buffer prior SDS-PAGE on 12%
Tris-Glycine gels and electroblotted (X-cell, invitrogen) onto
nitrocellulose membranes (Amersham). Membranes were probed
with rabbit anti-GFP antiserum and mouse anti-GAPDH mAb
(Cell Signaling, 14C10). Horseradish peroxidase (HRP)-conjugat-
ed goat anti-rabbit or rabbit anti-mouse antibodies (DAKO)
served as secondary reagents and the enhanced chemiluminiscence
(ECL; Amersham) system was used for detection.
Cell death assays
Primary lymph node cells, thymocytes and splenocytes derived
from transgenic mice isolated after sacrifice were kept in culture
as indicated above and percentage of viable cells was determined
by staining with 2 mg/mL propidium iodide plus AnnexinV-
APC (Biolegend) in annexin binding buffer (0.1 M HEPES/
NaOH, pH7.4; 140 mM NaCL; 25 mM CaCl2) and analyzing
the samples using a FACS_Calibur instrument (Becton Dick-
inson).
Flow cytometric analysis
Single-cell suspensions from peripheral blood, thymus, spleen,
inguinal lymph nodes and bone marrow were surface stained with
monoclonal antibodies conjugated with R-PE, APC or biotin in
300 ml of PBS containing 2% rat serum plus antibody diluted
1:200 and incubated for at least 30 min on ice in the dark. If
necessary, cells were subjected to a second incubation step after a
washing step using streptavidin-RPE or streptavidin-PE-Cy7 (both
from DAKO) diluted 1:200 in PBS. The monoclonal antibodies
used and their specificities are as follows: GK1.5, anti-CD4; 3C7,
anti-CD25; RB6-8C5, anti-Gr-1 (all Biolegend); MI/70, anti-
MAC-1; 11/26C, anti-IgD; R2/60, anti-CD43; MB19-1, anti-
CD19; II/41, anti-IgM 53-6.7, anti-CD8; (all eBioscience).
Biotinylated antibodies were detected using streptavidin-RPE
(DAKO) or streptavidin-PE-Cy7 (Becton Dickinson). Flow cyto-
metric analysis was performed using a FACS_Calibur cell analyzer
(BD Biosciences) and 100.000-200.000 events were acquired for
analysis.
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Statistical analysis was performed using the unpaired Student t test
and a Stat-view 4.1 software program. P-values of ,0.05 were
considered to indicate statistically significant differences.
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